Triveni Bio
Triveni Bio raises $115M Series B at $550M valuation
Triveni Bio: Series B Funding Round
Triveni Bio has successfully raised $115M in Series B funding, reaching a valuation of $550M.
Company Overview
Advancing preclinical antibody programs for immunological disorders
Funding Details
The Series B round was led by Lightspeed Venture Partners, with participation from GV.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Employees: 85+
- Category: Biotech
Investment
Triveni Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Lightspeed Venture Partners: Verified investor in Series B
- GV: Verified investor in Series B
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free